$CRTG
CORETEC GROUP INC.

2023 Q4 Form 10-Q Financial Statement

#000143774923030862 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $833.4K $310.0K
YoY Change -13.24% 2.99%
% of Gross Profit
Research & Development $178.5K $101.1K
YoY Change 31.93% 26.1%
% of Gross Profit
Depreciation & Amortization $25.13K $30.00K
YoY Change 9.12% 31.23%
% of Gross Profit
Operating Expenses $813.2K $101.1K
YoY Change -25.45% 26.1%
Operating Profit
YoY Change
Interest Expense -$56.14K $54.49K
YoY Change 3.05% 3.14%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$869.3K -$460.0K
YoY Change -24.1% 6.56%
Income Tax
% Of Pretax Income
Net Earnings -$869.3K -$456.6K
YoY Change -24.1% 5.78%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 284.1M 284.1M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $524.0K $1.020M
YoY Change -77.76% -63.26%
Cash & Equivalents $524.0K $1.020M
Short-Term Investments
Other Short-Term Assets $132.7K $190.0K
YoY Change 16.18% 46.47%
Inventory
Prepaid Expenses $132.7K $185.7K
Receivables
Other Receivables
Total Short-Term Assets $656.7K $1.206M
YoY Change -73.42% -58.5%
LONG-TERM ASSETS
Property, Plant & Equipment $109.8K $110.8K
YoY Change 49.42% 46.09%
Goodwill $166.0K $166.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.550K $0.00
YoY Change 0.0% -100.0%
Total Long-Term Assets $1.105M $1.126M
YoY Change -4.02% -4.06%
TOTAL ASSETS
Total Short-Term Assets $656.7K $1.206M
Total Long-Term Assets $1.105M $1.126M
Total Assets $1.761M $2.332M
YoY Change -51.37% -42.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $75.92K $310.0K
YoY Change -76.05% 2.29%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $571.5K $360.0K
YoY Change 830.7% 293.44%
Long-Term Debt Due $476.1K
YoY Change
Total Short-Term Liabilities $647.4K $671.7K
YoY Change 71.09% 70.23%
LONG-TERM LIABILITIES
Long-Term Debt $1.004M $1.245M
YoY Change -29.05% -10.97%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.004M $1.245M
YoY Change -29.05% -10.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $647.4K $671.7K
Total Long-Term Liabilities $1.004M $1.245M
Total Liabilities $1.651M $1.917M
YoY Change -7.92% 6.9%
SHAREHOLDERS EQUITY
Retained Earnings -$18.65M -$17.78M
YoY Change 14.12% 17.0%
Common Stock $56.82K $56.82K
YoY Change 5.67% 10.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $110.1K $415.5K
YoY Change
Total Liabilities & Shareholders Equity $1.761M $2.332M
YoY Change -51.37% -42.83%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$869.3K -$456.6K
YoY Change -24.1% 5.78%
Depreciation, Depletion And Amortization $25.13K $30.00K
YoY Change 9.12% 31.23%
Cash From Operating Activities -$609.0K -$410.0K
YoY Change 23.75% -14.74%
INVESTING ACTIVITIES
Capital Expenditures $2.860K $10.00K
YoY Change -243.06%
Acquisitions
YoY Change
Other Investing Activities $4.250K
YoY Change
Cash From Investing Activities $1.390K -$10.00K
YoY Change 43.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 115.2K -20.00K
YoY Change 59.2% -112.52%
NET CHANGE
Cash From Operating Activities -609.0K -410.0K
Cash From Investing Activities 1.390K -10.00K
Cash From Financing Activities 115.2K -20.00K
Net Change In Cash -492.4K -440.0K
YoY Change 17.31% 34.13%
FREE CASH FLOW
Cash From Operating Activities -$609.0K -$410.0K
Capital Expenditures $2.860K $10.00K
Free Cash Flow -$611.8K -$420.0K
YoY Change 24.33% -11.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
865978 usd
CY2023Q3 crtg Stock Issued During Period Value Issued For Liabilities
StockIssuedDuringPeriodValueIssuedForLiabilities
6126 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
434002 usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4517 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001375195
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101094 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80167 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
305560 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
301004 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
54491 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
52831 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
461145 usd
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2324 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-456628 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-431678 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.002
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.002
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
282965333
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
256912934
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-507384 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1320936 usd
CY2023Q2 crtg Stock Issued During Period Value Issued For Liabilities
StockIssuedDuringPeriodValueIssuedForLiabilities
18087 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-474295 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-456628 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
415476 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3864151 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
70973 usd
CY2022Q1 crtg Stock Issued During Period Value Issued For Liabilities
StockIssuedDuringPeriodValueIssuedForLiabilities
17298 usd
CY2022Q1 crtg Stock Issued During Period Value Stock Options Exchanged For Common Shares
StockIssuedDuringPeriodValueStockOptionsExchangedForCommonShares
0 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-679342 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
3273080 usd
CY2022Q2 crtg Stock Issued During Period Value Issued For Liabilities
StockIssuedDuringPeriodValueIssuedForLiabilities
20567 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
18723 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-606969 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2705401 usd
CY2022Q3 crtg Stock Issued During Period Value Issued For Liabilities
StockIssuedDuringPeriodValueIssuedForLiabilities
8864 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4101 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-431678 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4053327 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2286688 usd
us-gaap Net Income Loss
NetIncomeLoss
-1438307 usd
us-gaap Net Income Loss
NetIncomeLoss
-1717989 usd
us-gaap Depreciation
Depreciation
8706 usd
us-gaap Depreciation
Depreciation
4430 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
61973 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
61972 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
48799 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
45394 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
89696 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-85304 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-105215 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-0 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-11793 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
18830 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
42701 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1214695 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1356788 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46034 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
80265 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
76597 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
9946 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1250 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
169749 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-75347 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
159803 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1336076 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1277250 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2356348 usd
CY2022 crtg Stock Issued During Period Shares Stock Options Exchanged For Common Shares
StockIssuedDuringPeriodSharesStockOptionsExchangedForCommonShares
5700000
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2814000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1020272 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2776077 usd
us-gaap Interest Paid Net
InterestPaidNet
106571 usd
us-gaap Interest Paid Net
InterestPaidNet
106783 usd
crtg Noncash Insurance Premiums Financed
NoncashInsurancePremiumsFinanced
156806 usd
crtg Noncash Insurance Premiums Financed
NoncashInsurancePremiumsFinanced
0 usd
crtg Stock Options Exchanged For Common Stock
StockOptionsExchangedForCommonStock
0 usd
crtg Stock Options Exchanged For Common Stock
StockOptionsExchangedForCommonStock
180 usd
crtg Stock Issued To Settle Liabilities From Services Received
StockIssuedToSettleLiabilitiesFromServicesReceived
24213 usd
crtg Stock Issued To Settle Liabilities From Services Received
StockIssuedToSettleLiabilitiesFromServicesReceived
46729 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
242442697
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
241242697
us-gaap Net Income Loss
NetIncomeLoss
-17783620 usd
CY2023Q3 crtg Working Capital Deficit
WorkingCapitalDeficit
545243 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
567005 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
505032 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
845002 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
906975 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1245189 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1414826 usd
crtg Amortization Associated With Commitment Fee
AmortizationAssociatedWithCommitmentFee
13011 usd
crtg Amortization Associated With Commitment Fee
AmortizationAssociatedWithCommitmentFee
11048 usd
CY2020Q2 crtg Share Exchange Agreement Number Of Options Authorized
ShareExchangeAgreementNumberOfOptionsAuthorized
21500000
CY2020Q2 crtg Share Exchange Agreement Exchange Ratio
ShareExchangeAgreementExchangeRatio
0.6 rate
crtg Share Based Compensation Arrangement By Share Based Payment Award Options Exchanged
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchanged
9500000
crtg Stock Issued During Period Shares Stock Options Exchanged For Common Shares
StockIssuedDuringPeriodSharesStockOptionsExchangedForCommonShares
5700000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
132514000
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0555
CY2022 crtg Class Of Warrant Or Right Contractual Term
ClassOfWarrantOrRightContractualTerm
P3Y7M17D
crtg Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
12500000
crtg Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0.0001
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
120014000
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0612
crtg Class Of Warrant Or Right Contractual Term
ClassOfWarrantOrRightContractualTerm
P2Y10M17D
CY2023Q3 crtg Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
1018500 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
89696 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
77158160
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.070
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
77158160
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.070
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y11M19D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
77158160
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.070
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y11M19D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2023Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
77158160
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P2Y11M19D
CY2023Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
77158160
us-gaap Operating Lease Expense
OperatingLeaseExpense
40950 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
29952 usd

Files In Submission

Name View Source Status
0001437749-23-030862-index-headers.html Edgar Link pending
0001437749-23-030862-index.html Edgar Link pending
0001437749-23-030862.txt Edgar Link pending
0001437749-23-030862-xbrl.zip Edgar Link pending
crtg-20230930.xsd Edgar Link pending
crtg20230930_10q.htm Edgar Link pending
crtg20230930_10qimg011.jpg Edgar Link pending
ex_589995.htm Edgar Link pending
ex_589996.htm Edgar Link pending
ex_589997.htm Edgar Link pending
ex_589998.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
crtg20230930_10q_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
crtg-20230930_pre.xml Edgar Link unprocessable
crtg-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
crtg-20230930_def.xml Edgar Link unprocessable
crtg-20230930_lab.xml Edgar Link unprocessable